|
|
|
| Effect of paeoniflorin on vascular endothelial growth factor induced tubule formation of human umbilical vein endothelial cells |
| CHI Xiaowei1 CHEN Gangling2 |
1.Development Center for Medical Science & Technology, National Health Commission of the People’s Republic of China, Beijing 100044, China;
2.School of Traditional Chinese Pharmacy, China Pharmaceutical University, Jiangsu Province, Nanjing 211198, China |
|
|
|
Abstract Objective To study the effects of paeoniflorin (PF) on vascular endothelial growth factor (VEGF) induced tubule formation of human umbilical vein endothelial cells (HUVECs). Methods The HUVECs cell lines were resuscitated and cultured. MTT assay was used to determine the effects of different concentrations of PF (1, 3, 10, 30, 100 μmol/L) on HUVECs cell viability and the increase of cell viability induced by VEGF. Tubule formation experiments were conducted to evaluate the effect of different concentrations of PF (1, 3, 10, 30, 100 μmol/L) on VEGF induced tubule formation of HUVECs. The effect of PF (1, 3, 10, 30, 100 μmol/L) on VEGF induced HUVECs migration was evaluated by cell scratch test. Results Compared with blank group, there was no statistical significance in the effect of different concentrations of PF (1, 3, 10, 30, 100 μmol/L) on HUVECs cell viability (P ＞ 0.05). Compared with model group (VEGF was given 10 ng/mL, the same as below), there was no statistical significance in the effect of different concentrations of PF (1, 3, 10, 30, 100 μmol/L) on VEGF induced increased HUVECs cell viability (P ＞ 0.05). Compared with model group, different concentrations of PF (1, 3, 10, 30, 100 μmol/L) could inhibit the tubule formation of HUVECs induced by VEGF in vitro. Compared with model group, the scratch width ratio of 24 h/0 h in 10, 30 and 100 μmol/L PF dosage groups were all significantly higher than that in model group, with highly statistical significance (all P ＜ 0.01). Conclusion PF inhibits VEGF induced tubule formation of HUVECs in vitro, and this effect may be realized by inhibiting VEGF induced HUVECs migration.
|
|
|
|
|
|
[1] Rajabi M，Mousa SA. The Role of Angiogenesis in Cancer Treatment [J]. Biomedicines，2017，5（2）：34.
[2] Moriya J，Minamino T. Angiogenesis，Cancer，and Vascular Aging [J]. Front Cardiovasc Med，2017，4：65.
[3] Folkman J. Angiogenesis in cancer，vascular，rheumatoid and other disease [J]. Nature Med，1995，1（1）：27-31.
[4] Bai JY，Jin B，Ma JB，et al. HOTAIR and androgen receptor synergistically increase GLI2 transcription to promote tumor angiogenesis and cancer stemness in renal cell carcinoma [J]. Cancer Lett，2021，498：70-79.
[5] Zhu Z，Hou Q，Guo H. NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis，angiogenesis and tumor-associated macrophage recruit ment：A mechanism involving VEGF signaling [J]. Exp Cell Res，2020，397（1）：112311.
[6] Singh S，Pandey S，Chawla AS，et al. Dietary 2-deoxy-D-glucose impairs tumor growth and metastasis by inhibiting angiogenesis [J]. Eur J Cancer，2019，123：11-24.
[7] Choi J，Lee DH，Park SY，et al. Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer [J]. Biomed Pharmacother，2019，117：109091.
[8] Palazon A，Tyrakis PA，Macias D，et al. An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression [J]. Cancer Cell，2017，32（5）：669-683.
[9] Choi HS，Min KK，Lee K，et al. SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2 [J]. Oncotarget，2016，7（22）：32969-32979.
[10] Ye S，Mao B，Yang L，et al. Thrombosis recanalization by paeoniflorin through the upregulation of urokinase type plasminogen activator via the MAPK signaling pathway [J]. Mol Med Rep，2016，13（6）：4593-4598.
[11] Wu W，Qiu C，Feng X，et al. Protective Effect of Paeoniflorin on Acute Cerebral Infarction in Rats [J]. Curr Pharm Biotechnol，2020，21（8）：702-709.
[12] Wei YY，La L，Wang LL，et al. Paeoniflorin and liquiritin，two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders，inhibits prolactin secretion in prolactinoma cells by different mechanisms [J]. J Ethnopharmacol，2017，204：36-44.
[13] Cheng WX，Huang H，Chen JH，et al. Genistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6/JAK2/STAT3/VEGF signalling pathway [J]. J Orthop Translat，2019，22：92-100.
[14] Wang F，Chen F，Shang Y，et al. Insulin resistance adipocyte-derived exosomes aggravate atherosclerosis by increasing vasa vasorum angiogenesis in diabetic ApoE/ mice [J]. Int J Cardiol，2018，265：181-187.
[15] Schr?觟der H，Komljenovic D，Hecker M，et al. Transdermal drug targeting and functional imaging of tumor blood vessels in the mouse auricle [J]. FASEB J，2016，30（2）：923-932.
[16] Lee YH，Bae SC. Correlation between circulating VEGF levels and disease activity in rheumatoid arthritis： a meta-analysis [J]. Z Rheumatol，2018，77（3）：240-248.
[17] Gong Y，Yu Z，Wang Y，et al. Effect of Moxibustion on HIF-1α and VEGF Levels in Patients with Rheumatoid Arthritis [J]. Pain Res Manag，2019，2019：4705247.
[18] Bergers G，Benjamin LE. Tumorigenesis and the angiogenic switch [J]. Nat Rev Cancer，2003，3（6）：401-410.
[19] Li H，Zhao B，Liu Y，et al. Angiogenesis in residual cancer and roles of HIF-1α，VEGF，and MMP-9 in the development of residual cancer after radiofrequency ablation and surgical resection in rabbits with liver cancer [J]. Folia Morphol（Warsz），2020，79（1）：71-78.
[20] de Araújo Pimenta L，de Almeida MES，Bretones ML，et al. Crotoxin promotes macrophage reprogramming towards an antiangiogenic phenotype [J]. Sci Rep，2019，9（1）：4281.
[21] Zhang L，Deng Y，Zhang Y，et al. The Design，Characterizations，and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody With bFGF/VEGFA [J]. Front Oncol，2020，10：1190.
[22] Lacal PM，Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1（VEGFR-1）targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors [J]. Pharmacol Res，2018，136：97-107.
[23] Kong ZH，Hong Y，Zhu J，et al. Endothelial progenitor cells improve functional recovery in focal cerebral ischemia of rat by promoting angiogenesis via VEGF [J]. J Clin Neurosci，2018，55：116-121.
[24] Thomas KA. Vascular endothelial growth factor，a potent and selective angiogenic agent [J]. J Biol Chem，1996， 271（2）：603-606.
[25] Jain RK. Molecular regulation of vessel maturation [J]. Nat Med，2003，9（6）：685-693. |
|
|
|
